Clearly, the observed benefits of CAMKK2 inhibition on systemic metabolism will need to be formally tested in diverse models of ADT-driven metabolic syndrome to provide a more comprehensive evaluation of anti-CAMKK2-mediated efficacy. This evidence concerns the gene CAMKK2 and metabolic syndrome.